Post COVID 19 Lung Parenchymal Disease Management Experience with Follow up Outcomes in Qatar: A Case Series
Phool Iqbal1,2*, Muhammad Bilal Jamshaid1,3, Aamir Shahzad1,4, Zohaib Yousaf1,5, Saba Nabavi Monfared 6, Nagham D Sadik1 and Ibrahim Fawzy Hassan2
1Internal Medicine Department, Hamad Medical Corporation, Qatar.
2Medicine Critical Care Department, Hamad Medical Corporation, Qatar.
3Department of Rheumatology, Hamad Medical Corporation, Qatar
4Reading Hospital, Tower health, Pennsylvania, USA
5Dresden International University, Dresden, Germany.
6Trauma & Emergency Clinical Pharmacist Department, Hamad Medical Corporation, Qatar.
Citation: Iqbal P, Jamshaid MB, Shahzad A, Yousaf Z, Monfared SN et al (2021) Post COVID 19 Lung Parenchymal Disease Management Experience with Follow up Outcomes in Qatar: A Case Series. SciTech Biomed-Pharma Sciences 2021.
Received: August 18, 2021 Accepted: August 20, 2021 Published: August 20, 2021
Abstract
Background: COVID 19 has resulted in one of the worst global pandemics in recent history. Post-COVID 19 interstitial lung disease is a significant concern in COVID-19 survivors. It is a disabling clinical condition for the patients and a burden on the healthcare system. With the passage of time and subsequent different waves of COVID 19 across the globe, post-COVID 19 sequelae of lung diseases can be debilitating.
Case Series: We report case series of three patients with persistent hypoxia post-COVID 19, raising concerns for interstitial lung disease in Qatar. We shared our experience of the patient's clinical course, complications, and outcomes in post-COVID 19 sequelae of lung parenchymal disease.
Results: The patients were followed up during and after treatment until recovery or discharge from the hospital.
Conclusion: Through our case series, we want to highlight few points. First, the approach and management strategy of post-COVID 19 lung parenchymal disease patients is individualized. Sequelae of Post COVID 19 interstitial lung disease do not follow the same course during the follow-up period, and outcomes may differ. Two different entities are reported with regards to post-COVID 19 lung parenchymal disease. Post-COVID 19 fibrotic lung disease and fibrotic-like lesions follow different clinical courses, management strategies, and outcomes. Therefore, further studies for categorization of post-COVID 19 lungs parenchymal disease and adequate follow-up at regular time intervals are required.
Keywords: Post Covid 19, Lung fibrosis, ICU, anti-fibrotic, Pulmonary rehabilitation
